Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency

Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency

The development of safe and potent vaccines for human respiratory syncytial virus (HRSV) is still a challenge for researchers worldwide. DNA-based immunization is currently a promising approach that has been used to generate human vaccines for different age groups. In this study, novel HRSV DNA vacc...

Full description

Bibliographic Details
Main Authors: Mohamed A. Farrag, Haitham M. Amer, Peter Öhlschläger, Maaweya E. Hamad, Fahad N. Almajhdi
Format: Article
Language:English
Published: Taylor & Francis Group 2017-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
dna vaccine
disease enhancement
fusion protein
human respiratory syncytial virus
ppoe vector
truncated form
Online Access:http://dx.doi.org/10.1080/21645515.2017.1295190

Internet

http://dx.doi.org/10.1080/21645515.2017.1295190

Similar Items